MiMedx Group Inc. said Nasdaq granted its request for a listing extension and a hearing for more time to regain compliance with the exchange's listing rules.

The Marietta, Ga.-based biopharmaceutical company previously received a delisting notice from Nasdaq for failing to file its quarterly earnings report for the period ended March 31 during an initial compliance period.

The company said it was unable to file the periodic report on a timely manner due to an ongoing internal investigation by its audit committee over its sales and distribution practices, as well as other matters.

The hearing with Nasdaq Listing Qualifications is scheduled for Sept. 13.

MiMedx noted that there is no assurance the panel will grant its request for continued listing.